| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/CID/CIS636 |
| P8608 | Fatcat ID | release_b2g7jlooxzderocdzfoqq4pnkq |
| P698 | PubMed publication ID | 22843781 |
| P5875 | ResearchGate publication ID | 230586145 |
| P50 | author | Timothy M. Uyeki | Q84362200 |
| Janice K Louie | Q99552606 | ||
| P2093 | author name string | Cynthia Yen | |
| Meileen Acosta | |||
| Robert Schechter | |||
| Samuel Yang | |||
| Michael C Samuel | |||
| Hugo Guevara | |||
| P2860 | cites work | Time lines of infection and disease in human influenza: a review of volunteer challenge studies | Q34743132 |
| Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada | Q37055208 | ||
| End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease | Q37737726 | ||
| Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group | Q40625504 | ||
| Outcomes of adults hospitalised with severe influenza. | Q43044944 | ||
| Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina | Q43125690 | ||
| Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 | Q28260987 | ||
| Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. | Q30382272 | ||
| Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States | Q30388312 | ||
| Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection | Q30388857 | ||
| Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. | Q30393490 | ||
| Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients | Q30394867 | ||
| Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China | Q30398438 | ||
| Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. | Q30400544 | ||
| Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. | Q30400874 | ||
| Duration of viral shedding in hospitalized patients infected with pandemic H1N1 | Q30403064 | ||
| Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? | Q30403081 | ||
| Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico | Q30404888 | ||
| Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series | Q33360515 | ||
| Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome | Q33474780 | ||
| Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials | Q34192909 | ||
| Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. | Q34217769 | ||
| Viral shedding and clinical illness in naturally acquired influenza virus infections | Q34695139 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 1198-1204 | |
| P577 | publication date | 2012-07-26 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. | |
| P478 | volume | 55 |
| Q36376234 | A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients |
| Q88370045 | A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 |
| Q33743865 | A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head |
| Q97643797 | A metabolic handbook for the COVID-19 pandemic |
| Q30457132 | Advances in antivirals for non-influenza respiratory virus infections |
| Q30372931 | An overview of the characteristics of the novel avian influenza A H7N9 virus in humans. |
| Q90465416 | Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial |
| Q39118405 | Antiviral Treatments |
| Q30366719 | Antiviral combinations for severe influenza. |
| Q30210112 | Antivirals for influenza: where now for clinical practice and pandemic preparedness? |
| Q30425358 | Antivirals in seasonal and pandemic influenza--future perspectives |
| Q94491308 | Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP) |
| Q99401090 | COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy |
| Q64134362 | Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa |
| Q50057094 | Clinical characteristics of influenza virus-induced lower respiratory infection during the 2015 to 2016 season |
| Q37724526 | Comparative Epidemiology of Human Fatal Infections with Novel, High (H5N6 and H5N1) and Low (H7N9 and H9N2) Pathogenicity Avian Influenza A Viruses. |
| Q39907415 | Comparison of High-Dose Versus Standard Dose Oseltamivir in Critically Ill Patients With Influenza. |
| Q87461636 | Critical care management of adults with community-acquired severe respiratory viral infection |
| Q42227194 | Critically ill patients with influenza A(H1N1)pdm09 virus infection in 2014. |
| Q90408426 | Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America |
| Q30352949 | Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany |
| Q43865089 | Editorial commentary. "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never? |
| Q51731375 | Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons. |
| Q31155532 | Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection |
| Q40152886 | Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial |
| Q34341070 | Epidemiology of human infections with avian influenza A(H7N9) virus in China. |
| Q57789742 | Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza |
| Q52592172 | Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. |
| Q33799835 | Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus |
| Q41395483 | Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015. |
| Q30391411 | Human Influenza Virus Infections |
| Q39966481 | Impact of HIV on the severity of influenza |
| Q41019102 | Impact of Prompt Influenza Antiviral Treatment on Extended Care Needs After Influenza Hospitalization Among Community-Dwelling Older Adults |
| Q28537982 | Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study |
| Q30381799 | Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. |
| Q30396792 | Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015 |
| Q33838098 | Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study |
| Q37218517 | Influenza SIRS with Minimal Pneumonitis |
| Q58546744 | Influenza and Viral Pneumonia |
| Q26739661 | Influenza and the use of oseltamivir in children |
| Q38304274 | Influenza treatment with oseltamivir outside of labeled recommendations |
| Q64936560 | Influenza virus-related critical illness: prevention, diagnosis, treatment. |
| Q30359271 | Influenza-associated intensive-care unit admissions and deaths - California, September 29, 2013-January 18, 2014. |
| Q60918080 | Influenza-induced rhabdomyolysis |
| Q40369515 | Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. |
| Q47627293 | Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. |
| Q40042197 | Maoto, a Traditional Japanese Herbal Medicine, Inhibits Uncoating of Influenza Virus. |
| Q30392472 | Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data |
| Q30374549 | Neuraminidase inhibitor therapy in a military population. |
| Q30356037 | Neuraminidase inhibitors for critically ill children with influenza. |
| Q30370599 | Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. |
| Q38361244 | Optimizing antiviral therapy for influenza: understanding the evidence |
| Q42239583 | Optimum timing of oseltamivir: lessons from Bangladesh |
| Q44857539 | Oseltamivir Dosing in Critically Ill Patients With Severe Influenza |
| Q30390145 | Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection. |
| Q42287342 | Oseltamivir resistance during treatment of H7N9 infection |
| Q42283189 | Patients hospitalized with laboratory-confirmed influenza during the 2010-2011 influenza season: exploring disease severity by virus type and subtype |
| Q38543777 | Peramivir: an intravenous neuraminidase inhibitor |
| Q40748977 | Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. |
| Q91782536 | Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm |
| Q41927260 | Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management. |
| Q35076802 | Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit |
| Q60958294 | Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant |
| Q30358632 | Respiratory viral infections among hospitalized adults: experience of a single tertiary healthcare hospital. |
| Q30398670 | Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. |
| Q30353217 | Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study |
| Q91910138 | Seasonal Human Influenza: Treatment Options |
| Q40680147 | Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients. |
| Q87052081 | Severe community-acquired pneumonia |
| Q64137492 | Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016 |
| Q30375212 | Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations. |
| Q95597751 | Surviving COVID-19: A disease tolerance perspective |
| Q37374096 | Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors |
| Q40047799 | The Impact of Obesity and Timely Antiviral Administration on Severe Influenza Outcomes Among Hospitalized Adults. |
| Q41589233 | The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment |
| Q45353653 | The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic |
| Q30243907 | The pharmacological management of severe influenza infection - 'existing and emerging therapies'. |
| Q47554935 | The role of adjuvant immunomodulatory agents for treatment of severe influenza |
| Q30357688 | Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic. |
| Q26852219 | What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia? |
Search more.